These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 24342031)

  • 21. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
    McKay RR; Werner L; Jacobus SJ; Jones A; Mostaghel EA; Marck BT; Choudhury AD; Pomerantz MM; Sweeney CJ; Slovin SF; Morris MJ; Kantoff PW; Taplin ME
    Cancer; 2019 Feb; 125(4):524-532. PubMed ID: 30427533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abiraterone acetate in the treatment of prostate cancer.
    Thakur A; Roy A; Ghosh A; Chhabra M; Banerjee S
    Biomed Pharmacother; 2018 May; 101():211-218. PubMed ID: 29494958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer.
    Wang Y; Dason S; Shayegan B
    Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
    Stuyckens K; Saad F; Xu XS; Ryan CJ; Smith MR; Griffin TW; Yu MK; Vermeulen A; Nandy P; Poggesi I
    Clin Pharmacokinet; 2014 Dec; 53(12):1149-60. PubMed ID: 25204404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O; Veccia A; Kinspergher S; Maines F
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
    Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
    BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
    Harshman LC; Taplin ME
    Adv Ther; 2013 Aug; 30(8):727-47. PubMed ID: 23979793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
    Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
    Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
    Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An up-to-date evaluation of abiraterone for the treatment of prostate cancer.
    Shpilsky J; Stevens J; Bubley G
    Expert Opin Pharmacother; 2021 Jul; 22(10):1227-1234. PubMed ID: 33856289
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
    Onal C; Sedef AM; Kose F; Oymak E; Guler OC; Sumbul AT; Aksoy S; Akkus Yildirim B; Besen AA; Muallaoglu S; Mertsoylu H; Ozyigit G
    Future Oncol; 2019 May; 15(13):1469-1479. PubMed ID: 30977383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
    Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
    Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
    [No Abstract]   [Full Text] [Related]  

  • 39. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
    Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
    Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence.
    Livi L; Detti B; Francolini G; Terziani F; Triggiani L; D'Angelillo RM; Ingrosso G
    Tumori; 2019 Aug; 105(4):277-281. PubMed ID: 30905318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.